At the company’s May 22 shareholder meeting, MannKind officials signaled that FDA approval of its inhaled diabetes Afrezza® Inhalation Powder is likely, according to a report in FierceDrugDelivery.

The company played patient testimony in support of Afrezza from the combination product’s April 1 advisory committee hearing of the FDA in which the committee voted in favor of the drug 13-1 for the treatment of Type 1 diabetes and 14-0 for the treatment of Type 2 diabetes … more